Skip to main content
Top
Published in: Drugs & Aging 7/2010

01-07-2010 | Original Research Article

Potential Medication Problems in Older Newly Diagnosed Cancer Patients in Canada during Cancer Treatment

A Prospective Pilot Cohort Study

Authors: Dr Martine T. E. Puts, Johanne Monette, Veronique Girre, Beatriz Costa-Lima, Christina Wolfson, Gerald Batist, Howard Bergman

Published in: Drugs & Aging | Issue 7/2010

Login to get access

Abstract

Introduction

Older cancer patients are possibly at an increased risk of medication-related problems because, typically, they receive many medications during their cancer treatment, both for the cancer itself and for supportive care.

Objectives

The aim of this study was to describe the number and severity of potential medication problems during treatment of cancer in the first year after diagnosis. We also sought to examine whether patients receiving systemic cancer treatment had more medication-related problems at 3, 6 and 12 months than those not receiving systemic cancer treatment.

Methods

This was a prospective pilot cohort study on health and vulnerability in older newly diagnosed cancer patients with 1-year follow-up. The study was conducted at Segal Cancer Centre, Jewish General Hospital, Montreal, Canada. Of 156 eligible patients, 112 agreed to participate (response 71.8%). The patients were aged ≥65 years and were newly diagnosed with breast, colorectal or lung cancer, lymphoma or multiple myeloma. Patients were asked for permission to obtain their list of medications from their pharmacist. The cancer treatment information was abstracted from the medical chart. Vigilance Santé software was used to identify the presence, type and severity of potential medication problems.

Results

The median number of medications was five at baseline, seven at 3 months and six at 6 and 12 months. At baseline, 247 potential medication problems were identified, followed by 273 at 3 months, 229 at 6 months and 188 at 12 months. About half of the patients at each follow-up had one or more moderate or severe potential medication problem. Patients receiving systemic cancer treatment had significantly fewer potential problems at 3 months than patients not receiving systemic cancer treatment, but no differences were observed at 6 and 12 months. The most common warnings were contraindications, interactions and miscellaneous warnings, and the cancer treatment was involved in 12% of all potential problems.

Conclusion

This study showed that the majority of older newly diagnosed cancer patients take prescribed medication and about two-thirds have potential medication problems, of which about half are of at least moderate severity. The cancer treatment was involved in only a small proportion of all potential drug problems.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185–91PubMedCrossRef Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185–91PubMedCrossRef
2.
go back to reference Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370: 173–84PubMedCrossRef Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370: 173–84PubMedCrossRef
3.
go back to reference Lindblad CI, Hanlon JT, Gross CR, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther 2006; 28: 1133–43PubMedCrossRef Lindblad CI, Hanlon JT, Gross CR, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther 2006; 28: 1133–43PubMedCrossRef
4.
go back to reference Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61: 511–5PubMedCrossRef Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61: 511–5PubMedCrossRef
5.
go back to reference Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother 2007; 5: 263–303PubMedCrossRef Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother 2007; 5: 263–303PubMedCrossRef
6.
go back to reference Balducci L. Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 2009; 23: 78–85 Balducci L. Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 2009; 23: 78–85
7.
go back to reference Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 2008; 9: 191–203PubMedCrossRef Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 2008; 9: 191–203PubMedCrossRef
8.
go back to reference Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35: 535–43PubMedCrossRef Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35: 535–43PubMedCrossRef
9.
go back to reference Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592–600PubMedCrossRef Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592–600PubMedCrossRef
10.
go back to reference Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005; 56: 286–90PubMedCrossRef Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005; 56: 286–90PubMedCrossRef
11.
go back to reference Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006; 24: 704–12PubMedCrossRef Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006; 24: 704–12PubMedCrossRef
12.
go back to reference Riechelmann RP, Krzyzanowska MK, O’Carroll A, et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 2007; 15: 1407–12PubMedCrossRef Riechelmann RP, Krzyzanowska MK, O’Carroll A, et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 2007; 15: 1407–12PubMedCrossRef
13.
go back to reference Blower P, de Wit R, Goodin S, et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117–42PubMedCrossRef Blower P, de Wit R, Goodin S, et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117–42PubMedCrossRef
14.
go back to reference Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007; 32: 169–75PubMedCrossRef Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007; 32: 169–75PubMedCrossRef
15.
go back to reference Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009; 20: 1907–12PubMedCrossRef Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009; 20: 1907–12PubMedCrossRef
16.
go back to reference Buajordet I, Ebbesen J, Erikssen J, et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327–41PubMedCrossRef Buajordet I, Ebbesen J, Erikssen J, et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327–41PubMedCrossRef
17.
go back to reference Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17: 745–8PubMedCrossRef Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17: 745–8PubMedCrossRef
18.
19.
go back to reference Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 2009; 7: 151–8PubMedCrossRef Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 2009; 7: 151–8PubMedCrossRef
20.
go back to reference Puts MT, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 2009; 26: 519–36PubMedCrossRef Puts MT, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 2009; 26: 519–36PubMedCrossRef
21.
go back to reference Puts MT, Monette J, Girre V, et al. Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention [letter]. BMC Cancer 2009 Aug 10; 9(1): 277PubMedCrossRef Puts MT, Monette J, Girre V, et al. Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention [letter]. BMC Cancer 2009 Aug 10; 9(1): 277PubMedCrossRef
22.
go back to reference Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative staging manual and coding instructions, version 01.04.00. 2004; NIH Publication Number 04-5496 Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative staging manual and coding instructions, version 01.04.00. 2004; NIH Publication Number 04-5496
23.
go back to reference Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease staging classification. Cancer Res 1971; 31: 1860–1PubMed Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease staging classification. Cancer Res 1971; 31: 1860–1PubMed
24.
go back to reference Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–54PubMedCrossRef Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–54PubMedCrossRef
25.
go back to reference Groll DL, Heyland DK, Caeser M, et al. Assessment of long-term physical function in acute respiratory distress syndrome (ARDS) patients: comparison of the Charlson Comorbidity Index and the Functional Comorbidity Index. Am J Phys Med Rehabil 2006; 85: 574–81PubMedCrossRef Groll DL, Heyland DK, Caeser M, et al. Assessment of long-term physical function in acute respiratory distress syndrome (ARDS) patients: comparison of the Charlson Comorbidity Index and the Functional Comorbidity Index. Am J Phys Med Rehabil 2006; 85: 574–81PubMedCrossRef
26.
go back to reference Groll DL, To T, Bombardier C, et al. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005; 58: 595–602PubMedCrossRef Groll DL, To T, Bombardier C, et al. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005; 58: 595–602PubMedCrossRef
27.
go back to reference Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55PubMedCrossRef Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55PubMedCrossRef
28.
go back to reference Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758–65PubMedCrossRef Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758–65PubMedCrossRef
29.
go back to reference Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007; 5: 31–9PubMedCrossRef Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007; 5: 31–9PubMedCrossRef
30.
go back to reference Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ 1996; 154: 1177–84PubMed Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ 1996; 154: 1177–84PubMed
31.
go back to reference Miller MF, Bellizzi KM, Sufian M, et al. Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study. J Am Diet Assoc 2008; 108: 483–94PubMedCrossRef Miller MF, Bellizzi KM, Sufian M, et al. Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study. J Am Diet Assoc 2008; 108: 483–94PubMedCrossRef
32.
go back to reference Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004 Jun 15; 22(12): 2489–503PubMedCrossRef Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004 Jun 15; 22(12): 2489–503PubMedCrossRef
33.
go back to reference Bardia A, Greeno E, Bauer BA. Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? J Support Oncol 2007; 5: 195–8PubMed Bardia A, Greeno E, Bauer BA. Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? J Support Oncol 2007; 5: 195–8PubMed
34.
go back to reference Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 2005; 12: 149–57PubMed Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 2005; 12: 149–57PubMed
35.
go back to reference Lee AH, Ingraham SE, Kopp M, et al. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 2006; 29: 178–82PubMedCrossRef Lee AH, Ingraham SE, Kopp M, et al. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 2006; 29: 178–82PubMedCrossRef
36.
go back to reference Hanigan MH, Dela Cruz BL, Thompson DM, et al. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract 2008; 14: 123–30PubMedCrossRef Hanigan MH, Dela Cruz BL, Thompson DM, et al. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract 2008; 14: 123–30PubMedCrossRef
37.
go back to reference Gupta D, Lis CG, Birdsall TC, et al. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005; 13: 912–9PubMedCrossRef Gupta D, Lis CG, Birdsall TC, et al. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005; 13: 912–9PubMedCrossRef
38.
go back to reference Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol 2002; 20: 39S–41SPubMedCrossRef Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol 2002; 20: 39S–41SPubMedCrossRef
39.
go back to reference Zed PJ, bu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178: 1563–9PubMedCrossRef Zed PJ, bu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178: 1563–9PubMedCrossRef
40.
go back to reference Oliveria SA, Yood MU, Campbell UB, et al. Treatment and referral patterns for colorectal cancer. Med Care 2004; 42: 901–6PubMedCrossRef Oliveria SA, Yood MU, Campbell UB, et al. Treatment and referral patterns for colorectal cancer. Med Care 2004; 42: 901–6PubMedCrossRef
41.
go back to reference Siminoff LA, Zhang A, Saunders Sturm CM, et al. Referral of breast cancer patients to medical oncologists after initial surgical management. Med Care 2000; 38: 696–704PubMedCrossRef Siminoff LA, Zhang A, Saunders Sturm CM, et al. Referral of breast cancer patients to medical oncologists after initial surgical management. Med Care 2000; 38: 696–704PubMedCrossRef
Metadata
Title
Potential Medication Problems in Older Newly Diagnosed Cancer Patients in Canada during Cancer Treatment
A Prospective Pilot Cohort Study
Authors
Dr Martine T. E. Puts
Johanne Monette
Veronique Girre
Beatriz Costa-Lima
Christina Wolfson
Gerald Batist
Howard Bergman
Publication date
01-07-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11537310-000000000-00000

Other articles of this Issue 7/2010

Drugs & Aging 7/2010 Go to the issue